A5065641708- Lung Cancer Treatments and Mutations
- Cancer, Hypoxia, and Metabolism
- Hepatocellular Carcinoma Treatment and Prognosis
- PI3K/AKT/mTOR signaling in cancer
- Computational Drug Discovery Methods
- vaccines and immunoinformatics approaches
- Colorectal Cancer Treatments and Studies
- Angiogenesis and VEGF in Cancer
- Extracellular vesicles in disease
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
University of Hassan II Casablanca
2024-2025
National Centre for Nuclear Energy, Science and Technology
2021-2024
Lung cancer (LC) mutations in the epidermal growth factor receptor (EGFR), phosphoinositide 3-kinase catalytic subunit alpha (PIK3CA), and human 2 (HER2) genes represent promising targets for personalized treatment strategies. This study aims to investigate mutation profiles of these Moroccan LC patients examine their correlation with clinicopathological features. In this prospective study, specimens were collected from 60 patients. Mutations specific regions EGFR (exons 18 – 21),...
Aim: Angiogenesis is a universal hallmark of all cancers involving variety proteins including vascular endothelial growth factor (VEGF). Extensive studies have explored the potential implications single nucleotide polymorphisms (SNPs) within VEGF-A in lung cancer (LC) susceptibility, tumor growth, and their effect on gene expression level. Accordingly, we planned present study to evaluate prevalence -460T/C (rs833061), -2578C/A (rs699947), -2549I/D (rs35569394) SNPs association with...
Background: Lung cancer (LC) is a lethal malignancy with late diagnosis and poor prognosis. During the last decade, identification of oncogenic driver alterations has noticeably changed therapeutic landscape contributed to emergence “oncogene addiction” concept precision medicine in oncology. Among these alterations, spotlight turned mutations KRAS BRAF genes, which have garnered significant attention due targeted therapies potential for personalized treatment strategies. Objective: Hence,...